Technology
Health
Biotechnology

Savara

$8.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (0.50%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Savara and other stocks, options, ETFs, and crypto commission-free!

About

Savara Inc. Common Stock, also called Savara, is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Read More Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Employees
33
Headquarters
Austin, Texas
Founded
2017
Market Cap
281.17M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
186.67K
High Today
$8.14
Low Today
$7.94
Open Price
$8.00
Volume
25.31K
52 Week High
$14.06
52 Week Low
$6.21

Collections

Technology
Health
Biotechnology
Medical
Pharmaceutical
2013 IPO
US
North America

News

Simply Wall StMar 15

Breakeven On The Horizon For Savara Inc. (NASDAQ:SVRA)

Savara Inc.’s (NASDAQ:SVRA): Savara Inc. operates as an orphan lung disease company. The US$287m market-cap company announced a latest loss of -US$61.5m on 31 December 2018 for its most recent financial year result. As path to profitability is the topic on SVRA’s investors mind, I’ve decided to gauge market sentiment. Below I will provide a high-level summary of the industry analysts’ expectations for SVRA. Check out our latest analysis for Savara SVRA is bordering on breakeven, according to the 7 Biotech...

76
The Motley FoolMar 13

Savara Inc. (SVRA) Q4 2018 Earnings Conference Call Transcript

Savara Inc. (NASDAQ:SVRA) Q4 2018 Earnings Conference Call , 5:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Hello, everyone, and welcome to the Savara Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call will be available on the Investors section of Savara's website at savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction or transm...

42
MarketBeatMar 3

Stock Price, News, & Analysis for Savara

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inh...

2

Earnings

-$0.90
-$0.68
-$0.45
-$0.23
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.36 per share
Actual
-$0.29 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.